WO2005118852A2 - A marker for prenatal diagnosis and monitoring - Google Patents
A marker for prenatal diagnosis and monitoring Download PDFInfo
- Publication number
- WO2005118852A2 WO2005118852A2 PCT/GB2005/002211 GB2005002211W WO2005118852A2 WO 2005118852 A2 WO2005118852 A2 WO 2005118852A2 GB 2005002211 W GB2005002211 W GB 2005002211W WO 2005118852 A2 WO2005118852 A2 WO 2005118852A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- maspin
- maspin gene
- blood sample
- pregnancy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- Fetal RNA present in maternal blood has also been established as a diagnostic tool for pregnancy-associated conditions.
- U.S. Patent Application No. 09/876,005 discloses non-invasive techniques based on detection of fetal RNA in maternal blood;
- U.S. Patent Application No. 10/759,783 further discloses that the amount of certain mRNA species (e.g., hCG-/3, hCRH, hPL, KISS1, TPFI2, and PLAC1) present in maternal blood can be used as markers for diagnosing, monitoring, or predicting pregnancy-related disorders such as preeclampsia, fetal chromosomal aneuploidy, and preterm labor.
- certain mRNA species e.g., hCG-/3, hCRH, hPL, KISS1, TPFI2, and PLAC1
- the mammary serine protease inhibitor (maspin) gene is identified for the first time as a gene containing regions differentially methylated 'in genomic DNA originated from a fetus or from an adult (e.g. , a pregnant women) due to the different status of gene expression.
- the differentially methylated fetal maspin gene allows proper identification or quantification of fetal and maternal DNA and therefore reliable diagnosis of prenatal conditions.
- this invention relates to a method for detecting or monitoring a pregnancy-associated disorder in a woman pregnant with a fetus.
- This method comprises the following steps: (a) obtaining a blood sample from the woman; (b) determining the methylation status of at least a portion of the maspin gene in the blood sample, wherein the portion of the maspin gene from the fetus and the portion from the woman are differentially methylated, thereby distinguishing the maspin gene from the woman and the maspin gene from the fetus in the blood sample; (c) determining the level of the fetal maspin gene; and (d) comparing the level of the fetal maspin gene with a standard control.
- an increase from the standard control indicates the presence or progression of a pregnancy- associated disorder.
- a decrease from the standard control indicates the presence or progression of a pregnancy-associated disorder.
- the blood sample is whole blood, h other embodiments, the blood sample is plasma or serum.
- the portion of the maspin gene from the woman is methylated and the portion from the maspin gene from the fetus is less methylated.
- step (b) is performed by treating the DNA present in the blood sample with a reagent that differentially modifies methylated and non-methylated DNA.
- An often-used reagent for differential modification of methylated and non-methylated DNA is bisulfite.
- Other suitable regents may include one or more enzymes that preferentially cleave either methylated or unmethylated DNA.
- Pregnancy-associated disorders can be detected or monitored by this method include preeclampsia, preterm labor, hyperemesis gravidarum, ectopic pregnancy, fetal chromosomal aneuploidy (such as trisomy 18, 21, or 13), and intrauterme growth retardation.
- this invention provides a method for detecting or monitoring a pregnancy-associated disorder in a woman pregnant with a fetus.
- the method comprises the following steps: (a) obtaining DNA in a blood sample from the woman; (b) treating the DNA from step (a) with bisulfite; (c) performing an amplification reaction using the DNA from step (b) and two primers to amplify at least a portion of the maspin gene, wherein the portion of the maspin gene from the fetal DNA and the portion of the maspin gene from the maternal DNA in the blood sample are differentially methylated, and wherein at least one of the two primers binds differentially to the portion of the maspin gene from the fetus; and (d) comparing the level of the amplified portion of the maspin gene from step (c) with a standard control.
- an increase from the standard control indicates the presence or progression of a pregnancy-associated disorder. In other cases, a decrease from the standard control indicates the presence or progression of a pregnancy-associated disorder.
- the blood sample is whole blood. In other embodiments, the blood sample is plasma or serum.
- Some exemplary amplification reactions include polymerase chain reaction (PCR), nucleic acid sequence based amplification, strand displacement reaction, and branched DNA amplification reaction.
- Pregnancy-associated disorders can be detected or monitored by this method include preeclampsia, preterm labor, hyperemesis gravidarum, ectopic pregnancy, fetal chromosomal aneuploidy (such as trisomy 18, 21, or 13), and intrauterine growth retardation.
- the methods of the invention may also be carried out without an active step of obtaining a sample from the patient, on a sample previously obtained from the patient or on a sample isolated therefrom (e.g. a blood plasma or serum sample).
- a sample isolated therefrom e.g. a blood plasma or serum sample.
- the methods may be ex vivo methods, excluding any step performed directly on the patient.
- this inventions relates to a method for detecting the maspin gene from a fetus in the blood of a pregnant woman.
- the method comprises the following steps: (a) obtaining a blood sample from the woman; and (b) detecting at least a portion of the maspin gene, wherein the portion of the maspin gene is differentially methylated from the portion of the maspin gene from the maternal DNA in the blood sample, thereby detecting the maspin gene from the fetus.
- the blood sample is whole blood. In other embodiments, the blood sample is plasma or serum.
- the invention relates to a method for detecting and monitoring a pregnancy- associated disorder.
- This method comprises the following steps: (a) obtaining DNA in a blood sample from the woman; (b) treating the DNA from step (a) with a reagent that differentially modifies methylated and non-methylated DNA; (c) determining the nucleotide sequence of at least a portion of the maspin gene from step (b); and (d) comparing the profile of the nucleotide sequences from step (c) with a standard control, wherein a change in the profile from the standard control indicates the presence or progression of a pregnancy- associated disorder.
- the reagent comprises bisulfite.
- the reagent may include one or more enzymes that preferentially cleave DNA when the DNA is either methylated or unmethylated.
- the blood sample is plasma or serum, h other embodiments, the method further comprises an amplification step of using the DNA from step (b) and two primers to amplify a portion of the maspin gene, wherein the portion of the maspin gene from the fetal DNA and the portion from the maternal DNA in the blood sample are differentially methylated, and wherein at least one of the two primers binds differentially to the portion of the maspin gene from the fetus.
- the amplification step is performed by polymerase chain reaction (PCR) or methylation-specific PCR; in another exemplary embodiment, step (c) is performed by mass spectrometry, primer extension, polynucleotide hybridization, real-time PCR, or electrophoresis.
- PCR polymerase chain reaction
- step (c) is performed by mass spectrometry, primer extension, polynucleotide hybridization, real-time PCR, or electrophoresis.
- this invention relates to a method for detecting trisomy 18 in a fetus in a pregnant woman.
- This method comprises the following steps: (a) obtaining DNA from a blood sample from the woman; (b) treating the DNA from step (a) with a reagent that differentially modifies methylated and non-methylated DNA; and (c) determining the levels of different alleles of the maspin gene from the fetal DNA, thereby determining the ratio of the alleles, wherein the different alleles have different methylation profile in at least portion of the maspin gene, and wherein an increase or a decrease in the ratio from a standard control indicates the presence of trisomy 18 in the fetus.
- the reagent comprises bisulfite.
- the reagent may include one or more enzymes that preferentially cleave DNA when the DNA is either methylated or unmethylated.
- the blood sample is plasma or serum.
- placental tissues or other fetal tissues may be used for comparison.
- the method further comprises an amplification step of using the DNA from step (b) to amplify of at least a portion of the maspin gene that is differentially methylated in the maspin gene from the fetal DNA and the maspin gene from the maternal DNA in the blood sample.
- the amplification step is performed by PCR or methylation-specific PCR; in another exemplary embodiment, step (c) is performed by mass spectrometry, primer extension, polynucleotide hybridization, real-time PCR, or electrophoresis.
- this invention relates to a method for detecting trisomy 18 in a fetus carried by a pregnant woman.
- the method includes the following steps: (a) obtaining a blood sample from the woman; (b) determining the methylation status of at least a portion of the maspin gene in the blood sample, wherein the portion of the maspin gene from the fetus and the portion from the woman are differentially methylated, thereby distinguishing the maspin gene from the woman and the maspin gene from the fetus in the blood sample; and (c) determining the levels of two different alleles of the fetal maspin gene, wherein a deviation of the ratio of the levels of the two alleles from 1:1 indicates trisomy 18 in the fetus.
- the two different alleles of the fetal maspin gene comprise a single nucleotide polymorphism (SNP).
- SNP single nucleotide polymorphism
- One exemplary SNP is located at 156 bp upstream from the transcription start site of the maspin gene.
- Fig. 1 Schematic representation of the maspin genomic sequence, including the promoter and exon 1. The position of 2 CpG islands are shown as solid black bars. Arrows marked “F” and “R” denote the location of the bisulfite sequencing primers used in our study. The genomic and exon sequences are derived from NT_025028 and NM_002639 (GenBank accession numbers). CpG sites are shown in small vertical bars underneath. [0018] Fig.2. Maspin promoter sequence after complete bisulfite conversion. The boxed sequence represents a fully methylated state at all CpG sites, which are numbered with respect to the transcription start site (+1). Bisulfite sequencing primers F and R are underlined with »> and ⁇ «, respectively.
- Methylation-specific PCR (MSP) primers are shown underneath.
- MF and MR are used for MMSP, which detects the methylated sequence
- UF and UR are for UMSP, which detects the unmethylated sequence.
- Artificial mismatches, shown in lowercase, were added to the 3 rd base from the 3' end of the primers to enhance specificity and sensitivity of the MSP assays.
- MP and UP are the TaqMan MGB (Minor Grove Binding) probes designed for the real-time quantitative MMSP and UMSP assays, respectively.
- Fig. 3 Percentage of methylation of cytosine residues in CpG sites of the maspin promoter. Data are shown for the paired placental tissue and maternal buffy coat from 8 first trimester pregnancies (Panel A), and 8 third trimester pregnancies (Panel B). The lines inside the boxes denote the medians. The boxes mark the interval between the 25th and 75th percentiles.
- FIG. 4 Schematic diagram depicting the design for the V-m spin MassEXTE D reaction.
- the location of the -156 SNP is indicated in square brackets.
- the A/C SNP when bisulfite converted and interrogated in the reverse sense becomes a T/A SNP.
- the nested primers for the V-maspin MassEXTEND reaction (line arrows) are indicated schematically. Nucleotide positions on the extension primer which correspond to the unmethylated CpG sites are indicated by the positions marked "A" (adenine).
- hME homogenous MassEXTEND.
- FIG.5. Schematic diagram for detecting fetal trisomy 18 in maternal plasma.
- the allelic ratio will be 1 :1. However, for a fetus with trisomy 18, the allelic ratio will deviate significantly from normal, and in one scenario may be 2: 1. This V-maspin assay can thus be used for the non-invasive diagnosis of trisomy 18 by molecular analysis of the maternal plasma.
- Fig. 6 Methylation status of CpG sites in the maspin promoter. Juxtaposed are data from placental tissues (Panel A) and corresponding maternal buffy coat (Panel B) from each of eight pregnancies in the first trimester (TPl 1, TP12, TP13, TP14, TP15, TP16, TP17, and TP21) and the same tissues (Panels C and D) from each of eight pregnancies in the third trimester (NP23, NP27, NP28, NP29, NP30, NP31, NP32, and NP40). Open and closed circles represent unmethylated and methylated cytosine residues, respectively. At least 9 randomly chosen clones, numbered in the column, were sequenced for each site of each tissue.
- Fig. 7 Box plots of V-maspin concentrations in first-, second- and third- trimester maternal plasma. Line within each box denotes the median. Limits of the box denote the 25 th and 75 th percentiles. Whiskers denote the 5 th and 95 th percentiles. Filled circles depict the outliers. [0024] Fig. 8. V-maspin concentration in maternal plasma before and 24 hours after delivery. Paired samples from the same pregnancy are depicted by identical symbols connected by a line.
- PET preeclamptic
- Normal healthy
- Fig. 11 Mass spectrometric tracings of maternal plasma V-maspin -156 SNP genotype in cases 310 and 454. The corresponding maternal blood cell and placental tissue genotypes for the two cases are shown in Table 1. In both mass spectra, the x-axis depicts the molecular weight of the detected extension products (shown as sharp peaks), while the y-axis depicts the intensity in arbitrary units. The expected positions of the A- and C-alleles are as marked. [0028] Fig. 12. Scatter plot of the ratios of the -156 SNP among placental U-maspin sequences in normal pregnancies and pregnancies involving a trisomy 18 fetus (T18). The ratios are determined by comparing the area of the peaks for each respective allele on the mass spectra.
- FIG. 13 Mass spectrometric tracing illustrating the V ⁇ maspin -156 SNP allelic frequency in two sample mixtures containing 95% DNA from maternal blood cells and 5% DNA from placental tissues obtained from pregnancies involving a karyotypically normal fetus.
- the x-axis depicts the molecular weight of the detected extension products (shown as sharp peaks), while the y-axis depicts the intensity in arbitrary units.
- the expected positions of the A- and C-alleles are as marked.
- pregnancy-associated disorder refers to any condition or disease that may affect a pregnant woman, the fetus the woman is carrying, or both the woman and the fetus. Such a condition or disease may manifest its symptoms during a limited time period, e.g., during pregnancy or delivery, or may last the entire life span of the fetus following its birth.
- a pregnancy-associated disorder include ectopic pregnancy, preeclampsia, preterm labor, and fetal chromosomal abnormalities such as trisomy 13, 18, or 21.
- epigenetic state refers to any structural feature at molecular level of a nucleic acid (e.g., DNA or RNA) other than the primary nucleotide sequence.
- a nucleic acid e.g., DNA or RNA
- the epigenetic state of a genomic DNA may include its secondary or tertiary structure determined or influenced by, e.g. , its methylation pattern or its association with cellular proteins.
- methylation profile or "methylation status,” when used in this application to describe the state of methylation of a gene, refers to the characteristics of a DNA fragment relevant to methylation. Such characteristics include, but are not limited to, whether any of the cytosine (C) residues within this DNA sequence are methylated, location of methylated C residue(s), percentage of methylated C at any particular stretch of residues, and allelic differences in methylation due to, e.g., difference in the origin of the alleles or the level of gene expression.
- C cytosine
- single nucleotide polymorphism refers to the polynucleotide sequence variation present at a single nucleotide residue within different alleles of the same gene, e.g., the maspin gene. This variation may occur within the coding region or non-coding region (i.e., in the promoter region) of a gene. Detection of one or more SNP allows differentiation of different alleles of a single gene.
- blood refers to a blood sample or preparation from a pregnant woman or a woman being tested for possible pregnancy.
- the term encompasses whole blood or any fractions of blood, such as serum and plasma as conventionally defined.
- bisulfite encompasses all types of bisulfites, such as sodium bisulfite, that are capable of chemically converting a cytosine (C) to a uracil (U) without chemically modifying a methylated cytosine and therefore can be used to differentially modify a DNA sequence based on the methylation status of the DNA.
- a reagent that "differentially modifies" methylated or non- methylated DNA encompasses any reagent that modifies methylated and/or unmethylated DNA in a process through which distinguishable products result from methylated and non- methylated DNA, thereby allowing the identification of the DNA methylation status.
- Such processes may include, but are not limited to, chemical reactions (such as a C ⁇ U conversion by bisulfite) and enzymatic treatment (such as cleavage by a mefhylation-dependent endonuclease).
- an enzyme that preferentially cleaves methylated DNA is one capable of cleaving a DNA molecule at a much higher efficiency when the DNA is methylated, whereas an enzyme that preferentially cleaves unmethylated DNA exhibits a significantly higher efficiency when the DNA is not methylated.
- the term "nucleic acid” or “polynucleotide” refers to deoxyribonucleic acids
- DNA DNA
- RNA ribonucleic acids
- DNA DNA
- RNA ribonucleic acids
- the term encompasses nucleic acids containing known analogs of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides.
- a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, single nucleotide polymorphisms (SNPs), and complementary sequences as well as the sequence explicitly indicated.
- degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxymosine residues (Batzer et al, Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al, J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al, Mol. Cell. Probes 8:91-98 (1994)).
- the term nucleic acid is used interchangeably with gene, ' cDNA, and mRNA encoded by a gene.
- gene means the segment of DNA involved in producing a polypeptide chain; it includes regions preceding and following the coding region (leader and trailer) involved in the transcription/translation of the gene product and the regulation of the transcription/translation, as well as intervening sequences (introns) between individual coding segments (exons).
- polypeptide polypeptide
- peptide protein
- protein protein
- amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers.
- the terms encompass amino acid chains of any length, including full-length proteins (i.e., antigens), wherein the amino acid residues are linked by covalent peptide bonds.
- amino acid refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids.
- Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, ⁇ - carboxyglutamate, and O-phosphoserine.
- Amino acids may be referred to herein by either the commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
- an “increase” or a “decrease” refers to a detectable positive or negative change in quantity from an established standard control.
- An increase is a positive change preferably at least 2-fold, more preferably at least 5-fold, and most preferably at least 10-fold of the control value.
- a decrease is a negative change preferably at least 50%, more preferably at least 80%, and most preferably at least 90% of the control.
- Other terms indicating quantitative changes or differences from a comparative basis, such as "less,” are used in this application in the same fashion as described above.
- a "polynucleotide hybridization method” as used herein refers to a method for detecting the presence and/or quantity of a polynucleotide based on its ability to form
- Primer refers to oligonucleotides that can be used in an amplification method, such as a polymerase chain reaction (PCR), to amplify a nucleotide sequence based on the polynucleotide sequence corresponding to a gene of interest, e.g., the maspin gene in various methylation states. At least one of the PCR primers for amplification of a polynucleotide sequence is sequence- specific for the sequence.
- PCR polymerase chain reaction
- Standard control refers to a sample comprising a gene of a predetermined amount or methylation profile (which may include multiple different and separable characteristics related to methylation) suitable for the use of a method of the present invention, in order for comparing the amount or methylation status of a particular gene, e.g., the maspin gene, that is present in a test sample.
- a sample serving as a standard control provides an average amount or methylation profile of a gene of interest that is typical for a defined time (e.g. , first trimester) during pregnancy in the blood of an average, healthy pregnant woman carrying a normal fetus, both of who are not at risk of developing any pregnancy-associated disorders or complications.
- a particular gene e.g., the maspin gene
- This selected group should comprise a sufficient number of women such that the average amount or methylation profile of the gene of interest among these women reflects, with reasonable accuracy, the corresponding profile in the general population of healthy pregnant women with healthy fetuses.
- the selected group of women generally have a similar gestational age to that of a woman whose blood is tested for indication of a potential pregnancy-associated disorder.
- the preferred gestational age for practicing the present invention may vary depends on the disorder that is being screened for. For example, a pregnant woman is screened for the risk of preeclampsia preferably during the second trimester of the pregnancy, whereas fetal chromosomal aneuploidy is preferably screened for
- the preferred gestational age for testing may also depend on the gene of interest in testing.
- preeclampsia refers to a condition that occurs during pregnancy, the main symptom of which is various forms of high blood pressure often accompanied by the presence of proteins in the urine and edema (swelling).
- Preeclampsia sometimes called toxemia of pregnancy, is related to a more serious disorder called "eclampsia,” which is preeclampsia together with seizures.
- eclampsia a more serious disorder
- preeclampsia which is preeclampsia together with seizures.
- hypoesthesiaesis gravidarum refers to extreme, persistent nausea and vomiting during pregnancy, particularly during the first trimester. The nausea and vomiting may lead to dehydration and prevent necessary weight gain for the pregnancy.
- An "ectopic pregnancy” refers to an abnormal pregnancy in which a fertilized egg has implanted outside the uterus. Although in most cases of ectopic pregnancy the egg settles in the fallopian tubes, this term also encompasses abnormal pregnancies where the fertilized egg is implanted in a woman's ovary, abdomen, or cervix. DETAILED DESCRIPTION OF THE INVENTION
- Methylation is an epigenetic phenomenon, which refers to processes that alter a phenotype without involving changes in the DNA sequence.
- placenta-derived RNA can be detected in maternal plasma (Ng et al, Proc. Natl. Acad. Sci. USA 100:4748-4753, 2003).
- the predominant source of maternal DNA is derived from peripheral blood cells while the placenta is a possible source of fetal DNA release into maternal plasma.
- one strategy for the development of a generic fetal-specific DNA marker for detection in. maternal plasma is to identify a gene that is differentially methylated between the placenta and the maternal peripheral blood cells.
- Maspin is a protein belonging to the family of serine protease inhibitors. It is found to be expressed in a variety of normal tissues, mainly those of epithelial origin, such as breast, prostate, placenta, testis, colon and the small intestines. The clinical significance of maspin was realized when a study by Zou et al. (Science 263:526-529, 1994) demonstrated its reduced expression in human breast carcinoma cells. Subsequent studies noted an inverse relationship between its expression and cancer
- maspin gene is widely accepted as a tumor suppressor gene, whose physiological function lies in the promotion of cell-matrix adhesion and the inhibition of cell invasion. Investigations fail to reveal DNA mutations that are responsible for the altered expression of maspin in tumors. Instead, maspin was found to be under epigenetic control where expression is suppressed by promoter methylation and histone deacetylation (Futscher et al, Nat. Genet. 31:175-179, 2002; Maass et al, Biochem. Biophys. Res. Commun. 297:125-128, 2002).
- the maspin gene is differentially methylated between the fetal DNA from the fetus (e.g., from the placenta) and the maternal DNA from the mother's peripheral blood cells. This discovery thus provides a new approach for distinguishing fetal and maternal DNA and new methods for non-invasive prenatal diagnosis.
- nucleic acids sizes are given in either kilobases (kb) or base pairs (bp). These are estimates derived from agarose or acrylamide gel electrophoresis, from sequenced nucleic acids, or from published DNA sequences.
- kb kilobases
- bp base pairs
- proteins sizes are given in kilodaltons (kDa) or amino acid residue numbers. Protein sizes are estimated from gel electrophoresis, from sequenced proteins, from derived amino acid sequences, or from published protein sequences.
- Ohgonucleotides that are not commercially available can be chemically synthesized, e.g., according to the solid phase phosphoramidite triester method first described by Beaucage & Caruthers, Tetrahedron Lett. 22: 1859-1862 (1981), using an automated synthesizer, as described in NanDevanter et. al, Nucleic Acids Res. 12: 6159-6168 (1984). Purification of ohgonucleotides is performed using any art-recognized strategy, e.g. , native acrylamide gel electrophoresis or anion-exchange high performance liquid chromatography (HPLC) as described in Pearson & Reanier, J. Chrom. 255: 137-149 (1983).
- HPLC high performance liquid chromatography
- the present invention relates to analyzing the epigenetic status of fetal DNA found in maternal blood as a non-invasive means to detect the presence and/or to monitor the progress of a pregnancy-associated condition or disorder.
- the first steps of practicing this invention are to obtain or provide a blood sample from a pregnant woman and extract DNA from the sample.
- a blood sample is obtained from a pregnant woman at a gestational age suitable for testing using a method of the present invention.
- the suitable gestational age may vary depending on the disorder tested, as discussed below. Collection of blood from a woman is performed in accordance with the standard protocol hospitals or clinics generally follow. An appropriate amount of peripheral blood, e.g., typically between 5-50 ml, is collected and maybe stored according to standard procedure prior to further preparation.
- the analysis of fetal DNA found in maternal blood may be performed using, e.g., the whole blood, serum, or plasma.
- the methods for preparing serum or plasma from maternal blood are well known among those of skill in the art.
- a pregnant woman's blood can be placed in a tube containing EDT A or a specialized commercial product such as Vacutainer SST (Becton Dickinson, Franklin Lakes, NJ) to prevent blood clotting, and plasma can then be obtained from whole blood through centrifugation.
- serum may be obtained with or without centrifugation following blood clotting.
- centrifugation is typically, though not exclusively, conducted at an appropriate speed, e.g., 1,500-3,000 x g. Plasma or serum may be subjected to additional centrifugation steps before being transferred to a fresh tube for DNA extraction.
- DNA may also be recovered from the cellular fraction, enriched in the buffy coat portion, which can be obtained following centrifugation of a whole blood sample from the woman and removal of the plasma.
- the DNA Upon being extracted from a blood sample of a pregnant woman, the DNA is treated with a reagent capable of chemically modifying DNA in a methylation differential manner, i.e., different and distinguishable chemical structures will result from a methylated cytosine (C) residue and an unmethylated C residue following the treatment.
- a reagent capable of chemically modifying DNA in a methylation differential manner, i.e., different and distinguishable chemical structures will result from a methylated cytosine (C) residue and an unmethylated C residue following the treatment.
- a reagent reacts with the unmethylated C residue(s) in a DNA molecule and converts each unmethylated C residue to a uracil (U) residue, whereas the methylated C residues remain unchanged.
- This C ⁇ U conversio ⁇ he ⁇ eteetiorir ⁇ d-eom ari ⁇ based on changes in the primary sequence of the nucleic acid.
- An exemplary reagent suitable for this purpose is bisulfite, such as sodium bisulfite.
- bisulfite such as sodium bisulfite.
- Methods for using bisulfite for chemical modification of DNA are well known in the art (see, e.g. , Herman et al. , Proc. Natl. Acad. Sci. USA 93:9821-9826, 1996) and will not be discussed in detail here.
- any other reagents that are unnamed here but have the same property of chemically (or through any other mechanism) modifying methylated and unmethylated DNA differentially can be used for practicing the present invention.
- methylation-specific modification of DNA may also be accomplished by methylation-sensitive restriction enzymes, some of which typically cleave an unmethylated DNA fragment but not a methylated DNA fragment, while others (e.g., methylation-dependent endonuclease McrBC) cleave DNA containing methylated cytosines but not unmethylated DNA.
- McrBC methylation-dependent endonuclease
- a combination of chemical modification and restriction enzyme treatment e.g. , combined bisulfite restriction analysis (COBRA) may be used for practicing the present invention.
- COBRA combined bisulfite restriction analysis
- the treated D ⁇ A is then subjected to sequence-based analysis, such that the maspin gene from the fetal D ⁇ A may be distinguished from the maspin gene from the maternal D ⁇ A, and that fetal maspin gene methylation profile may be determined and compared to a standard control.
- An amplification reaction is optional prior to the maspin gene sequence analysis after methylation specific modification.
- the amplification is performed to preferentially amplify a portion of the maspin gene that has a particular methylation pattern, such that only the maspin gene from one particular source, e.g., from the placenta or other tissues of the fetus, is detected and analyzed.
- PCR polymerase chain reaction
- PCR is most usually carried out as an automated process with a thermostable enzyme. In this process, the temperature of the reaction mixture is cycled through a denaturing region, a primer annealing region, and an extension reaction region automatically. Machines specifically adapted for this purpose are commercially available.
- PCR amplification of a target polynucleotide sequence is typically used in practicing the present invention
- amplification of a maspin gene sequence found in a maternal blood sample may be accomplished by any known method, such as ligase chain reaction (LCR), transcription- mediated amplification, and self-sustained sequence replication or nucleic acid sequence- based amplification (NASBA), each of which provides sufficient amplification.
- LCR ligase chain reaction
- NASBA nucleic acid sequence- based amplification
- More recently developed branched-DNA technology may also be used to qualitatively demonstrate the presence of a particular maspin gene sequence (which represents a particular methylation pattern), or to quantitatively determine the amount of a particular maspin gene sequence
- Additional means suitable for detecting changes (e.g., C ⁇ U) in a polynucleotide sequence for practicing the methods of the present invention include but are not limited to mass spectrometry, primer extension, polynucleotide hybridization, real-time PCR, and electrophoresis.
- a group of healthy pregnant women carrying healthy fetuses are first selected. These women are of similar gestational age, which is within the appropriate time period of pregnancy for screening of conditions such as preeclampsia, fetal chromosomal aneuploidy, and preterm labor using the methods of the present invention. Similarly, a standard control is established using samples from a group of healthy non-pregnant women.
- the healthy status of the selected pregnant women and the fetuses they are carrying are confirmed by well established, routinely employed methods including but not limited to monitoring blood pressure of the women, recording the onset of labor, and conducting fetal genetic analysis using CVS and amniocentesis.
- the selected group of healthy pregnant women carrying healthy fetuses must be of a reasonable size, such that the average amount of fetal maspin gene in the maternal blood or the methylation profile of at least a portion of the fetal maspin gene in the maternal blood obtained from the group can be reasonably regarded as representative of the normal or average amount or methylation profile among the general population of healthy women carrying healthy fetuses.
- the selected group comprises at least 10 women.
- a standard control for fetal maspin gene methylation profile may reflect multiple different and separable aspects of the methylation status of this gene. For example, one aspect of a methylation profile is whether the C residue is methylated or not; another aspect is the number of methylated C bases within a particular region of the maspin gene; a further aspect of the profile is the percentage(s) of methylated C at any given locations. Additional aspects of a methylation profile may include, but are not limited to, the allelic difference in methylation, the ratio of differentially methylated alleles, and the like. Fetal maspin gene methylation profile may also vary depending on the tissue type, e.g., placental or other fetal tissue. Thus, separate standard controls may be established for different fetal tissues used in testing.
- the inventors included both male (TP12, TP14, TP15, TP17, NP27, NP28, NP29, NP30, NP31, NP40) and female fetuses (TPl 1, TP13, TP16, TP21, NP23, NP32) for this part of the study.
- the PCR product was TA-cloned into a plasmid vector using the pGEM- T Easy Vector System (Promega, Madison, WI) and the inserts from at least 10 positive recombinant clones were analyzed by cycle sequencing using the BigDye Terminator Cycle Sequencing vl.l kit (Applied Biosystems) as per the manufacturer's instructions. After purification by genCLEAN columns (Genetix), 8 ⁇ l of the samples were added to 12 ⁇ l of Hi-Di formamide and run on a 3100 DNA Analyzer (Applied Biosystems).
- a CpG site was scored as methylated if the sequence was cytosine; scored as unmethylated if it was occupied by a thymine residue (deoxy counterpart of uracil).
- the proportion of methylated cytosine residue for each CpG site in each type of tissues was determined for each pregnancy.
- the distribution of methylated and unmethylated cytosines were compared between the placental tissues and maternal buffy coat for each CpG site (Fig. 3).
- SPSS Sigma Stat 3.0 software
- Fetal DNA coexists with a background of maternal DNA in plasma of pregnant women. As demonstrated previously, plasma DNA is predominantly derived from blood cells in normal, non-pregnant subjects. Based on this, it is hypothesized that maternal DNA in maternal plasma is also predominantly derived from maternal blood cells in which the
- maspin promoter is densely methylated.
- fetal RNA detected in maternal plasma is derived from the placenta.
- the contribution of fetal DNA in maternal plasma may also originate from the placenta and hence possess the same methylation status in the maspin promoter as that of the placenta.
- the maspin promoter in placenta may be umnethylated, which would be different from the background of methylated maspin promoter of the maternal origin, it was examined if this epigenetic difference would allow fetal-specific detection of placenta-derived maspin DNA in maternal plasma. It was examined whether unmethylated maspin sequences would: (a) be detectable in plasma of pregnant women;
- Methylation-specific PCR primer design Based on the methylation map generated from study (1) above, primers that discriminate between the unmethylated and methylated versions of the maspin promoter were designed, based on the principles of methylation-specific PCR (MSP) (Herman et al, Proc. Natl. Acad. Sci. USA 93:9821-9826, 1996). The assays specific for the unmethylated maspin (V-maspin) and methylated maspin (M-maspin) promoters were designated as UMSP and MMSP, respectively. The primers for UMSP (UF and UR) and for MMSP (MF and MP) are shown in Fig. 2.
- MSP methylation-specific PCR
- Placenta-derived maspin DNA can therefore be used as a marker for predicting, detecting, diagnosing and monitoring pregnancy-associated disorders, including, but not limited to preeclampsia, preterm labor, hyperemesis gravidarum, ectopic pregnancies, molar pregnancies, intrauterine growth retardation and chromosomal aneuploidies, such as fetal Down syndrome, fetal trisomy 18, fetal trisomy 13.
- Maternal plasma V-maspin concentration was determined by the real-time quantitative assay among 8 preeclamptic pregnant women bearing fetuses of both sexes (median gestational age: 36.1 weeks) and from 16 gestational age matched pregnant women without preeclampsia as controls (median gestational age: 36 weeks).
- SNP genotyping was performed on genomic DNA from the placental tissues and maternal blood cells using the standard primer extension (homogenous MassEXTEND (hME)) protocol on a MassARRAY system (SEQUENOM, San Diego, CA), which is a matrix-assisted laser desorption ionization/time-of-flight (MALDI-TOF) MS system (Tang et al, Proc. Natl. Acad. Sci. USA 96:10016-20, 1999).
- a method for determining the -156 SNP genotype among the V-maspin sequences in maternal plasma was then developed. 0.8 mL of plasma was bisulfite converted as described above.
- the maspin promoter was amplified using nested primers, shown as hME primary and secondary primers in Figure 4, by conventional PCR. MassEXTEND assay was performed according to manufacturer's instructions. The nested primers and extension primer were designed to anneal to V-maspin promoter sequences (Fig. 4).
- the extension reaction was performed using a terminator mix consisted of ddCTP, ddGTP, ddTTP and dATP. The extension reaction begins at the SNP site (Fig. 4).
- Genotyping of the -156 SNP was first performed on genomic DNA extracted from placental tissues collected from both normal and pregnancies involving a fetus with trisomy 18, Cases heterozygous for the -156 SNP were identified. DNA extracted from the placental tissues of these cases were bisulfite converted and V-maspin was amplified using the nested conventional PCR as described above. The MassEXTEND assay targeting the -156 V-maspin SNP alleles as described above was then applied to the PCR products.
- the abundance of the two V-maspin alleles at the -156 SNP was determined by comparing the respective peak areas for each allele as shown by the mass spectra determined by the MassARRAY system. As maspin is located on chromosome 18 m ⁇ V-maspin is derived from the placenta, the relative abundance of the two V-maspin alleles is reflective of the number of fetal chromosome 18 (Fig. 5). The reliability of the assay and allelic ratio determination was assessed by testing two sample mixtures comprised of 95% DNA from a maternal blood cell sample and 5% DNA from the
- V-maspin was detected in all the 8 samples of maternal plasma obtained from third trimester and all the 15 samples of maternal plasma obtained from third trimester, the 10
- V-maspin DNA concentration was measured in the plasma obtained from 8 preeclamptic pregnant women and 16 gestational age matched pregnant women without preeclampsia as controls.
- the median V-maspin concentration in maternal plasma was 5.7- fold elevated in the preeclamptic group (median 737.7 copies/mL, IQR 306.9-1397.0) relative to the control group (median 130.3 copies/mL, IQR 110.7-286.2) (Fig. 10).
- the -156 SNP is an A/C polymorphism.
- the fetal and maternal maspin genotypes shown in Table 1, were determined from 8 third-trimester pregnancies using genomic DNA collected from placental tissues and the corresponding maternal blood cells.
- MassEXTEND assay was designed to interrogate the -156 SNP among V-maspin promoter sequences.
- the A-allele of the -156 SNP would be extended by one base while the C-allele would be extended by two bases (Fig. 4) which are resolved as peaks of different masses on MS (Fig. 11).
- Maternal plasma samples from the eight pregnancies were bisulfite converted and the V-maspin -156 SNP genotype was assessed.
- the maternal plasma V-maspin genotypes were completely concordant with that of the placental tissues (Table 1). These data confirm that V-maspin in maternal plasma is derived from the placenta.
- Non-invasive prenatal diagnosis of trisomy 18 The use of the V-maspin system for the non-invasive prenatal diagnosis of trisomy 18 is illustrated in Figure 5. This strategy is possible because the maspin gene is located on chromosome 18.
- One embodiment of this strategy is the use of primer sequences which amplify unmethylated maspin sequences from maternal plasma. As demonstrated above these sequences are predominantly derived from the fetus.
- the primer sequences are designed such that they encompass one or more polymorphisms.
- one possible type of polymorphism is the single nucleotide polymorphism (SNP).
- SNP single nucleotide polymorphism
- the allelic ratio of the detected alleles can be measured, possibly by primer extension and mass spectrometry, or by other methods known to those skilled in the art. In one scenario, if the fetus has the normal situation of two chromosome 18, then the allelic ratio will be 1 to 1. If the fetus has the abnormal situation of three chromosome 18 (i.e., trisomy 18), then the allelic ratio will deviate from 1 to 1. As another illustration of this, the allelic ratio may become 2 to 1 or 1 to 2.
- the A:C allelic ratio for case A was 1.235 which is within the range of values obtained for karyotypically normal pregnancies (Fig. 12). These data confirm the applicability of the assay for allelic ratio determination in biological samples containing fetal DNA within a high background of maternal DNA, one example being fetal DNA in maternal plasma.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005250223A AU2005250223B2 (en) | 2004-06-04 | 2005-06-06 | A marker for prenatal diagnosis and monitoring |
EP05746652.6A EP1751307B1 (en) | 2004-06-04 | 2005-06-06 | A marker for prenatal diagnosis and monitoring |
CA2568755A CA2568755C (en) | 2004-06-04 | 2005-06-06 | A marker for prenatal diagnosis and monitoring |
HK07108112.9A HK1102196A1 (en) | 2004-06-04 | 2007-07-26 | A marker for prenatal diagnosis and monitoring |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57724204P | 2004-06-04 | 2004-06-04 | |
US60/577,242 | 2004-06-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005118852A2 true WO2005118852A2 (en) | 2005-12-15 |
WO2005118852A3 WO2005118852A3 (en) | 2006-03-16 |
Family
ID=35351726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2005/002211 WO2005118852A2 (en) | 2004-06-04 | 2005-06-06 | A marker for prenatal diagnosis and monitoring |
Country Status (6)
Country | Link |
---|---|
US (6) | US7709194B2 (en) |
EP (1) | EP1751307B1 (en) |
AU (1) | AU2005250223B2 (en) |
CA (1) | CA2568755C (en) |
HK (1) | HK1102196A1 (en) |
WO (1) | WO2005118852A2 (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007132166A2 (en) * | 2006-05-03 | 2007-11-22 | The Chinese University Of Hong Kong | New fetal methylation markers |
WO2007132167A3 (en) * | 2006-05-03 | 2008-05-22 | Univ Hong Kong Chinese | Novel fetal markers for prenatal diagnosis and monitoring |
US8008018B2 (en) | 2006-02-02 | 2011-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Determination of fetal aneuploidies by massively parallel DNA sequencing |
US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US8168389B2 (en) | 2006-06-14 | 2012-05-01 | The General Hospital Corporation | Fetal cell analysis using sample splitting |
US8195415B2 (en) | 2008-09-20 | 2012-06-05 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US8318430B2 (en) | 2010-01-23 | 2012-11-27 | Verinata Health, Inc. | Methods of fetal abnormality detection |
US8442774B2 (en) | 2007-07-23 | 2013-05-14 | The Chinese University Of Hong Kong | Diagnosing fetal chromosomal aneuploidy using paired end |
US8972202B2 (en) | 2007-07-23 | 2015-03-03 | The Chinese University Of Hong Kong | Diagnosing fetal chromosomal aneuploidy using massively parallel genomic sequencing |
WO2015169947A1 (en) * | 2014-05-09 | 2015-11-12 | Lifecodexx Ag | Detection of dna that originates from a specific cell-type and related methods |
WO2015159293A3 (en) * | 2014-04-14 | 2015-12-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | A method and kit for determining the tissue or cell origin of dna |
EP3168309A1 (en) | 2015-11-10 | 2017-05-17 | Lifecodexx AG | Detection of foetal chromosomal aneuploidies using dna regions that are differentially methylated between the foetus and the pregnant female |
US9822413B2 (en) | 2014-05-09 | 2017-11-21 | Lifecodexx Ag | Multiplex detection of DNA that originates from a specific cell-type |
US9822412B2 (en) | 2014-05-09 | 2017-11-21 | Lifecodexx Ag | Detection of DNA that originates from a specific cell-type |
US10364467B2 (en) | 2015-01-13 | 2019-07-30 | The Chinese University Of Hong Kong | Using size and number aberrations in plasma DNA for detecting cancer |
US10435754B2 (en) | 2006-09-27 | 2019-10-08 | The Chinese University Of Hong Kong | Diagnostic method |
US10591391B2 (en) | 2006-06-14 | 2020-03-17 | Verinata Health, Inc. | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US10612086B2 (en) | 2008-09-16 | 2020-04-07 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
US10704090B2 (en) | 2006-06-14 | 2020-07-07 | Verinata Health, Inc. | Fetal aneuploidy detection by sequencing |
US10738358B2 (en) | 2008-09-16 | 2020-08-11 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
US11062789B2 (en) | 2014-07-18 | 2021-07-13 | The Chinese University Of Hong Kong | Methylation pattern analysis of tissues in a DNA mixture |
US11060145B2 (en) | 2013-03-13 | 2021-07-13 | Sequenom, Inc. | Methods and compositions for identifying presence or absence of hypermethylation or hypomethylation locus |
US11306354B2 (en) | 2012-05-21 | 2022-04-19 | Sequenom, Inc. | Methods and compositions for analyzing nucleic acid |
US11312997B2 (en) | 2012-03-02 | 2022-04-26 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US11332791B2 (en) | 2012-07-13 | 2022-05-17 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
US11365447B2 (en) | 2014-03-13 | 2022-06-21 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US11410750B2 (en) | 2018-09-27 | 2022-08-09 | Grail, Llc | Methylation markers and targeted methylation probe panel |
US11435339B2 (en) | 2016-11-30 | 2022-09-06 | The Chinese University Of Hong Kong | Analysis of cell-free DNA in urine |
US12024750B2 (en) | 2020-10-01 | 2024-07-02 | Grail, Llc | Methylation markers and targeted methylation probe panel |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6927028B2 (en) * | 2001-08-31 | 2005-08-09 | Chinese University Of Hong Kong | Non-invasive methods for detecting non-host DNA in a host using epigenetic differences between the host and non-host DNA |
US7709194B2 (en) * | 2004-06-04 | 2010-05-04 | The Chinese University Of Hong Kong | Marker for prenatal diagnosis and monitoring |
US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US8532930B2 (en) | 2005-11-26 | 2013-09-10 | Natera, Inc. | Method for determining the number of copies of a chromosome in the genome of a target individual using genetic data from genetically related individuals |
US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US10083273B2 (en) | 2005-07-29 | 2018-09-25 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US10081839B2 (en) | 2005-07-29 | 2018-09-25 | Natera, Inc | System and method for cleaning noisy genetic data and determining chromosome copy number |
KR20080107464A (en) * | 2006-03-06 | 2008-12-10 | 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | Specific amplification of fetal dna sequences from a mixed, fetal-maternal source |
US8679741B2 (en) * | 2006-05-31 | 2014-03-25 | Sequenom, Inc. | Methods and compositions for the extraction and amplification of nucleic acid from a sample |
US7902345B2 (en) | 2006-12-05 | 2011-03-08 | Sequenom, Inc. | Detection and quantification of biomolecules using mass spectrometry |
ATE549419T1 (en) | 2007-08-29 | 2012-03-15 | Sequenom Inc | METHODS AND COMPOSITIONS FOR UNIVERSAL SIZE-SPECIFIC POLYMERASE CHAIN REACTION |
PT2240781T (en) | 2008-01-18 | 2018-03-28 | Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
WO2009105531A1 (en) * | 2008-02-19 | 2009-08-27 | Gene Security Network, Inc. | Methods for cell genotyping |
CA2717320A1 (en) * | 2008-03-11 | 2009-09-17 | Sequenom, Inc. | Nucleic acid-based tests for prenatal gender determination |
WO2009146335A1 (en) * | 2008-05-27 | 2009-12-03 | Gene Security Network, Inc. | Methods for embryo characterization and comparison |
WO2010017214A1 (en) * | 2008-08-04 | 2010-02-11 | Gene Security Network, Inc. | Methods for allele calling and ploidy calling |
WO2010045357A2 (en) * | 2008-10-15 | 2010-04-22 | Cornell University | Enhanced on-chip sers based biomolecular detection using electrokinetically active microwells |
US20100279295A1 (en) * | 2009-03-18 | 2010-11-04 | Sequenom, Inc. | Use of thermostable endonucleases for generating reporter molecules |
EP3211095B1 (en) | 2009-04-03 | 2019-01-02 | Sequenom, Inc. | Nucleic acid preparation compositions and methods |
ES2640776T3 (en) | 2009-09-30 | 2017-11-06 | Natera, Inc. | Methods for non-invasively calling prenatal ploidy |
CA2785020C (en) | 2009-12-22 | 2020-08-25 | Sequenom, Inc. | Processes and kits for identifying aneuploidy |
US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
CA2798758C (en) | 2010-05-18 | 2019-05-07 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11326208B2 (en) | 2010-05-18 | 2022-05-10 | Natera, Inc. | Methods for nested PCR amplification of cell-free DNA |
US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US20130203624A1 (en) | 2010-07-23 | 2013-08-08 | President And Fellows Of Harvard College | Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions |
AU2011280997A1 (en) | 2010-07-23 | 2013-02-28 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
KR20130041962A (en) | 2010-07-23 | 2013-04-25 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Methods of detecting diseases or conditions using phagocytic cells |
CA2806291C (en) | 2010-07-23 | 2023-08-29 | President And Fellows Of Harvard College | Methods for detecting signatures of disease or conditions in bodily fluids |
US10167508B2 (en) | 2010-08-06 | 2019-01-01 | Ariosa Diagnostics, Inc. | Detection of genetic abnormalities |
US10533223B2 (en) | 2010-08-06 | 2020-01-14 | Ariosa Diagnostics, Inc. | Detection of target nucleic acids using hybridization |
US20140342940A1 (en) | 2011-01-25 | 2014-11-20 | Ariosa Diagnostics, Inc. | Detection of Target Nucleic Acids using Hybridization |
US8700338B2 (en) | 2011-01-25 | 2014-04-15 | Ariosa Diagnosis, Inc. | Risk calculation for evaluation of fetal aneuploidy |
US11031095B2 (en) | 2010-08-06 | 2021-06-08 | Ariosa Diagnostics, Inc. | Assay systems for determination of fetal copy number variation |
US20130040375A1 (en) | 2011-08-08 | 2013-02-14 | Tandem Diagnotics, Inc. | Assay systems for genetic analysis |
US11203786B2 (en) | 2010-08-06 | 2021-12-21 | Ariosa Diagnostics, Inc. | Detection of target nucleic acids using hybridization |
US20120034603A1 (en) | 2010-08-06 | 2012-02-09 | Tandem Diagnostics, Inc. | Ligation-based detection of genetic variants |
US20130261003A1 (en) | 2010-08-06 | 2013-10-03 | Ariosa Diagnostics, In. | Ligation-based detection of genetic variants |
CN103534591B (en) | 2010-10-26 | 2016-04-06 | 利兰·斯坦福青年大学托管委员会 | The Noninvasive fetus genetic screening undertaken by sequencing analysis |
JP6328934B2 (en) | 2010-12-22 | 2018-05-23 | ナテラ, インコーポレイテッド | Noninvasive prenatal testing |
US9994897B2 (en) | 2013-03-08 | 2018-06-12 | Ariosa Diagnostics, Inc. | Non-invasive fetal sex determination |
US8756020B2 (en) | 2011-01-25 | 2014-06-17 | Ariosa Diagnostics, Inc. | Enhanced risk probabilities using biomolecule estimations |
US11270781B2 (en) | 2011-01-25 | 2022-03-08 | Ariosa Diagnostics, Inc. | Statistical analysis for non-invasive sex chromosome aneuploidy determination |
US10131947B2 (en) | 2011-01-25 | 2018-11-20 | Ariosa Diagnostics, Inc. | Noninvasive detection of fetal aneuploidy in egg donor pregnancies |
BR112013020220B1 (en) | 2011-02-09 | 2020-03-17 | Natera, Inc. | METHOD FOR DETERMINING THE PLOIDIA STATUS OF A CHROMOSOME IN A PREGNANT FETUS |
CA2827873C (en) | 2011-02-24 | 2022-08-16 | The Chinese University Of Hong Kong | Molecular testing of multiple pregnancies |
US8460872B2 (en) | 2011-04-29 | 2013-06-11 | Sequenom, Inc. | Quantification of a minority nucleic acid species |
US8712697B2 (en) | 2011-09-07 | 2014-04-29 | Ariosa Diagnostics, Inc. | Determination of copy number variations using binomial probability calculations |
WO2013053359A1 (en) | 2011-10-14 | 2013-04-18 | Aarhus Universitet | Diagnostic and prognostic use of prombp-complexes |
EP2820157B1 (en) | 2012-03-02 | 2019-05-01 | Winthrop-University Hospital | Method for using probe based pcr detection to measure the levels of circulating demethylated beta cell derived dna as a measure of beta cell loss in diabetes |
WO2013148496A1 (en) | 2012-03-26 | 2013-10-03 | The Johns Hopkins University | Rapid aneuploidy detection |
US10289800B2 (en) | 2012-05-21 | 2019-05-14 | Ariosa Diagnostics, Inc. | Processes for calculating phased fetal genomic sequences |
EP2875156A4 (en) | 2012-07-19 | 2016-02-24 | Ariosa Diagnostics Inc | Multiplexed sequential ligation-based detection of genetic variants |
US10494675B2 (en) | 2013-03-09 | 2019-12-03 | Cell Mdx, Llc | Methods of detecting cancer |
US11585814B2 (en) | 2013-03-09 | 2023-02-21 | Immunis.Ai, Inc. | Methods of detecting prostate cancer |
US20130189684A1 (en) * | 2013-03-12 | 2013-07-25 | Sequenom, Inc. | Quantification of cell-specific nucleic acid markers |
US20160369339A1 (en) * | 2013-07-01 | 2016-12-22 | Cindy Anderson | Biomarker for preeclampsia |
WO2015048535A1 (en) | 2013-09-27 | 2015-04-02 | Natera, Inc. | Prenatal diagnostic resting standards |
US10577655B2 (en) | 2013-09-27 | 2020-03-03 | Natera, Inc. | Cell free DNA diagnostic testing standards |
US10262755B2 (en) | 2014-04-21 | 2019-04-16 | Natera, Inc. | Detecting cancer mutations and aneuploidy in chromosomal segments |
AU2015249846B2 (en) | 2014-04-21 | 2021-07-22 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
AU2015314813B2 (en) | 2014-09-11 | 2022-02-24 | Immunis.Ai, Inc. | Methods of detecting prostate cancer |
US11479812B2 (en) | 2015-05-11 | 2022-10-25 | Natera, Inc. | Methods and compositions for determining ploidy |
DE102015009187B3 (en) * | 2015-07-16 | 2016-10-13 | Dimo Dietrich | Method for determining a mutation in genomic DNA, use of the method and kit for carrying out the method |
WO2018067517A1 (en) | 2016-10-04 | 2018-04-12 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
US10011870B2 (en) | 2016-12-07 | 2018-07-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
WO2018156418A1 (en) | 2017-02-21 | 2018-08-30 | Natera, Inc. | Compositions, methods, and kits for isolating nucleic acids |
WO2018187767A1 (en) * | 2017-04-06 | 2018-10-11 | The Regents Of The University Of California | Predicting, diagnosing, and treating nausea and vomiting of pregnancy |
EP3662480A4 (en) * | 2017-08-04 | 2021-05-19 | BillionToOne, Inc. | Target-associated molecules for characterization associated with biological targets |
AU2018312117B2 (en) | 2017-08-04 | 2022-05-12 | Billiontoone, Inc. | Sequencing output determination and analysis with target-associated molecules in quantification associated with biological targets |
US11519024B2 (en) | 2017-08-04 | 2022-12-06 | Billiontoone, Inc. | Homologous genomic regions for characterization associated with biological targets |
EP4335928A3 (en) | 2018-01-05 | 2024-04-17 | BillionToOne, Inc. | Quality control templates for ensuring validity of sequencing-based assays |
US11525159B2 (en) | 2018-07-03 | 2022-12-13 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9704444D0 (en) * | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
US6927028B2 (en) * | 2001-08-31 | 2005-08-09 | Chinese University Of Hong Kong | Non-invasive methods for detecting non-host DNA in a host using epigenetic differences between the host and non-host DNA |
JP2005514956A (en) * | 2002-01-18 | 2005-05-26 | ジェンザイム・コーポレーション | Methods for detection of fetal DNA and quantification of alleles |
EP1689884A4 (en) * | 2003-10-08 | 2007-04-04 | Univ Boston | Methods for prenatal diagnosis of chromosomal abnormalities |
US7709194B2 (en) * | 2004-06-04 | 2010-05-04 | The Chinese University Of Hong Kong | Marker for prenatal diagnosis and monitoring |
-
2005
- 2005-06-03 US US11/144,951 patent/US7709194B2/en active Active
- 2005-06-06 CA CA2568755A patent/CA2568755C/en active Active
- 2005-06-06 EP EP05746652.6A patent/EP1751307B1/en active Active
- 2005-06-06 WO PCT/GB2005/002211 patent/WO2005118852A2/en active Application Filing
- 2005-06-06 AU AU2005250223A patent/AU2005250223B2/en active Active
-
2007
- 2007-07-26 HK HK07108112.9A patent/HK1102196A1/en unknown
-
2010
- 2010-03-15 US US12/724,335 patent/US8026067B2/en active Active
-
2011
- 2011-08-22 US US13/215,024 patent/US20120003650A1/en not_active Abandoned
-
2016
- 2016-02-01 US US15/012,611 patent/US9862999B2/en active Active
-
2017
- 2017-12-14 US US15/842,718 patent/US10604808B2/en active Active
-
2020
- 2020-03-02 US US16/806,820 patent/US11597977B2/en active Active
Non-Patent Citations (1)
Title |
---|
None |
Cited By (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8008018B2 (en) | 2006-02-02 | 2011-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Determination of fetal aneuploidies by massively parallel DNA sequencing |
US9441273B2 (en) | 2006-02-02 | 2016-09-13 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive fetal genetic screening by digital analysis |
US9777328B2 (en) | 2006-02-02 | 2017-10-03 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive fetal genetic screening by digital analysis |
US9777329B2 (en) | 2006-02-02 | 2017-10-03 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive fetal genetic screening by digital analysis |
US10072295B2 (en) | 2006-02-02 | 2018-09-11 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive fetal genetic screening by digtal analysis |
US8293470B2 (en) | 2006-02-02 | 2012-10-23 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive fetal genetic screening by digital analysis |
US11692225B2 (en) | 2006-02-02 | 2023-07-04 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive fetal genetic screening by digital analysis |
EP3722443A1 (en) * | 2006-05-03 | 2020-10-14 | The Chinese University of Hong Kong | Novel markers for prenatal diagnosis and monitoring |
KR20200051674A (en) * | 2006-05-03 | 2020-05-13 | 더 차이니즈 유니버시티 오브 홍콩 | Novel fetal markers for prenatal diagnosis and monitoring |
EA014274B1 (en) * | 2006-05-03 | 2010-10-29 | Те Чайниз Юниверсити Ов Гонгконг | Novel fetal markers for prenatal diagnosis and monitoring |
EP2385142A1 (en) * | 2006-05-03 | 2011-11-09 | The Chinese University Of Hong Kong | Novel markers for prenatal diagnosis and monitoring |
EP4289969A3 (en) * | 2006-05-03 | 2024-06-19 | The Chinese University of Hong Kong | New fetal methylation marker |
US7754428B2 (en) | 2006-05-03 | 2010-07-13 | The Chinese University Of Hong Kong | Fetal methylation markers |
EP3875604A1 (en) * | 2006-05-03 | 2021-09-08 | The Chinese University of Hong Kong | New fetal methylation marker |
US8288100B2 (en) | 2006-05-03 | 2012-10-16 | The Chinese University Of Hong Kong | Methods for detecting fetal DNA in a plasma or serum sample from a pregnant woman |
KR102221745B1 (en) * | 2006-05-03 | 2021-02-26 | 더 차이니즈 유니버시티 오브 홍콩 | Novel fetal markers for prenatal diagnosis and monitoring |
JP2009535049A (en) * | 2006-05-03 | 2009-10-01 | ザ チャイニーズ ユニバーシティ オブ ホンコン | New fetal methylation marker |
KR102166398B1 (en) | 2006-05-03 | 2020-10-15 | 더 차이니즈 유니버시티 오브 홍콩 | Novel fetal markers for prenatal diagnosis and monitoring |
EP3133173A1 (en) * | 2006-05-03 | 2017-02-22 | The Chinese University of Hong Kong | New fetal methylation marker |
KR102129690B1 (en) | 2006-05-03 | 2020-07-02 | 더 차이니즈 유니버시티 오브 홍콩 | Novel fetal markers for prenatal diagnosis and monitoring |
AU2007251351B2 (en) * | 2006-05-03 | 2013-07-25 | The Chinese University Of Hong Kong | Novel fetal markers for prenatal diagnosis and monitoring |
AU2007251394B2 (en) * | 2006-05-03 | 2014-02-13 | The Chinese University Of Hong Kong | New fetal methylation markers |
US7901884B2 (en) | 2006-05-03 | 2011-03-08 | The Chinese University Of Hong Kong | Markers for prenatal diagnosis and monitoring |
KR20140097601A (en) * | 2006-05-03 | 2014-08-06 | 더 차이니즈 유니버시티 오브 홍콩 | Novel fetal markers for prenatal diagnosis and monitoring |
KR101456306B1 (en) * | 2006-05-03 | 2014-11-04 | 더 차이니즈 유니버시티 오브 홍콩 | Novel fetal markers for prenatal diagnosis and monitoring |
EP3505644A1 (en) * | 2006-05-03 | 2019-07-03 | The Chinese University Of Hong Kong | New fetal methylation marker |
WO2007132166A2 (en) * | 2006-05-03 | 2007-11-22 | The Chinese University Of Hong Kong | New fetal methylation markers |
KR20190049939A (en) * | 2006-05-03 | 2019-05-09 | 더 차이니즈 유니버시티 오브 홍콩 | Novel fetal markers for prenatal diagnosis and monitoring |
JP2009535050A (en) * | 2006-05-03 | 2009-10-01 | ザ チャイニーズ ユニバーシティ オブ ホンコン | New fetal markers for prenatal diagnosis and monitoring |
KR20180061418A (en) * | 2006-05-03 | 2018-06-07 | 더 차이니즈 유니버시티 오브 홍콩 | Novel fetal markers for prenatal diagnosis and monitoring |
KR101864921B1 (en) | 2006-05-03 | 2018-06-05 | 더 차이니즈 유니버시티 오브 홍콩 | Novel fetal markers for prenatal diagnosis and monitoring |
EP3299477A1 (en) * | 2006-05-03 | 2018-03-28 | The Chinese University of Hong Kong | New fetal methylation marker |
CN107354218A (en) * | 2006-05-03 | 2017-11-17 | 香港中文大学 | New fetus mark for pre-natal diagnosis and monitoring |
CN101512014A (en) * | 2006-05-03 | 2009-08-19 | 香港中文大学 | New fetal methylation markers |
WO2007132167A3 (en) * | 2006-05-03 | 2008-05-22 | Univ Hong Kong Chinese | Novel fetal markers for prenatal diagnosis and monitoring |
CN102758014B (en) * | 2006-05-03 | 2017-09-22 | 香港中文大学 | New fetus mark for pre-natal diagnosis and monitoring |
WO2007132166A3 (en) * | 2006-05-03 | 2008-02-21 | Univ Hong Kong Chinese | New fetal methylation markers |
EP3085792A1 (en) * | 2006-05-03 | 2016-10-26 | The Chinese University of Hong Kong | Novel markers for prenatal diagnosis and monitoring |
US9017942B2 (en) | 2006-06-14 | 2015-04-28 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US8372584B2 (en) | 2006-06-14 | 2013-02-12 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US10435751B2 (en) | 2006-06-14 | 2019-10-08 | Verinata Health, Inc. | Methods for the diagnosis of fetal abnormalities |
US11781187B2 (en) | 2006-06-14 | 2023-10-10 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US8168389B2 (en) | 2006-06-14 | 2012-05-01 | The General Hospital Corporation | Fetal cell analysis using sample splitting |
US11674176B2 (en) | 2006-06-14 | 2023-06-13 | Verinata Health, Inc | Fetal aneuploidy detection by sequencing |
US9347100B2 (en) | 2006-06-14 | 2016-05-24 | Gpb Scientific, Llc | Rare cell analysis using sample splitting and DNA tags |
US9273355B2 (en) | 2006-06-14 | 2016-03-01 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US11261492B2 (en) | 2006-06-14 | 2022-03-01 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US10591391B2 (en) | 2006-06-14 | 2020-03-17 | Verinata Health, Inc. | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US10155984B2 (en) | 2006-06-14 | 2018-12-18 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US10704090B2 (en) | 2006-06-14 | 2020-07-07 | Verinata Health, Inc. | Fetal aneuploidy detection by sequencing |
US10041119B2 (en) | 2006-06-14 | 2018-08-07 | Verinata Health, Inc. | Methods for the diagnosis of fetal abnormalities |
US10435754B2 (en) | 2006-09-27 | 2019-10-08 | The Chinese University Of Hong Kong | Diagnostic method |
US11898208B2 (en) | 2006-09-27 | 2024-02-13 | The Chinese University Of Hong Kong | Diagnostic method |
US10619214B2 (en) | 2007-07-23 | 2020-04-14 | The Chinese University Of Hong Kong | Detecting genetic aberrations associated with cancer using genomic sequencing |
US8442774B2 (en) | 2007-07-23 | 2013-05-14 | The Chinese University Of Hong Kong | Diagnosing fetal chromosomal aneuploidy using paired end |
US9121069B2 (en) | 2007-07-23 | 2015-09-01 | The Chinese University Of Hong Kong | Diagnosing cancer using genomic sequencing |
US9051616B2 (en) | 2007-07-23 | 2015-06-09 | The Chinese University Of Hong Kong | Diagnosing fetal chromosomal aneuploidy using massively parallel genomic sequencing |
US8972202B2 (en) | 2007-07-23 | 2015-03-03 | The Chinese University Of Hong Kong | Diagnosing fetal chromosomal aneuploidy using massively parallel genomic sequencing |
US11142799B2 (en) | 2007-07-23 | 2021-10-12 | The Chinese University Of Hong Kong | Detecting chromosomal aberrations associated with cancer using genomic sequencing |
US10738358B2 (en) | 2008-09-16 | 2020-08-11 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
US10612086B2 (en) | 2008-09-16 | 2020-04-07 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
US9404157B2 (en) | 2008-09-20 | 2016-08-02 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US8682594B2 (en) | 2008-09-20 | 2014-03-25 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US10669585B2 (en) | 2008-09-20 | 2020-06-02 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US9353414B2 (en) | 2008-09-20 | 2016-05-31 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US8195415B2 (en) | 2008-09-20 | 2012-06-05 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US8296076B2 (en) | 2008-09-20 | 2012-10-23 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuoploidy by sequencing |
US8318430B2 (en) | 2010-01-23 | 2012-11-27 | Verinata Health, Inc. | Methods of fetal abnormality detection |
US10718020B2 (en) | 2010-01-23 | 2020-07-21 | Verinata Health, Inc. | Methods of fetal abnormality detection |
US9493831B2 (en) | 2010-01-23 | 2016-11-15 | Verinata Health, Inc. | Methods of fetal abnormality detection |
US11312997B2 (en) | 2012-03-02 | 2022-04-26 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US11306354B2 (en) | 2012-05-21 | 2022-04-19 | Sequenom, Inc. | Methods and compositions for analyzing nucleic acid |
US11332791B2 (en) | 2012-07-13 | 2022-05-17 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
US11060145B2 (en) | 2013-03-13 | 2021-07-13 | Sequenom, Inc. | Methods and compositions for identifying presence or absence of hypermethylation or hypomethylation locus |
US11365447B2 (en) | 2014-03-13 | 2022-06-21 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2015159292A3 (en) * | 2014-04-14 | 2015-12-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | A method and kit for determining the tissue or cell origin of dna |
CN106574296B (en) * | 2014-04-14 | 2021-03-02 | 耶路撒冷希伯来大学伊森姆研究发展公司 | Method and kit for determining tissue or cell origin of DNA |
WO2015159293A3 (en) * | 2014-04-14 | 2015-12-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | A method and kit for determining the tissue or cell origin of dna |
CN106574296A (en) * | 2014-04-14 | 2017-04-19 | 耶路撒冷希伯来大学伊森姆研究发展公司 | A method and kit for determining the tissue or cell origin of DNA |
US11203784B2 (en) | 2014-04-14 | 2021-12-21 | Hadasit Medical Research Services And Development Ltd. | Method and kit for determining the tissue or cell origin of DNA |
US9822413B2 (en) | 2014-05-09 | 2017-11-21 | Lifecodexx Ag | Multiplex detection of DNA that originates from a specific cell-type |
US11773443B2 (en) | 2014-05-09 | 2023-10-03 | Eurofins Lifecodexx Gmbh | Multiplex detection of DNA that originates from a specific cell-type |
US9822412B2 (en) | 2014-05-09 | 2017-11-21 | Lifecodexx Ag | Detection of DNA that originates from a specific cell-type |
US10801067B2 (en) | 2014-05-09 | 2020-10-13 | Eurofins Lifecodexx Gmbh | Detection of DNA that originates from a specific cell-type and related methods |
WO2015169947A1 (en) * | 2014-05-09 | 2015-11-12 | Lifecodexx Ag | Detection of dna that originates from a specific cell-type and related methods |
US11965207B2 (en) | 2014-05-09 | 2024-04-23 | Eurofins Lifecodexx Gmbh | Detection of DNA that originates from a specific cell-type and related methods |
US10017818B2 (en) | 2014-05-09 | 2018-07-10 | Lifecodexx Ag | Multiplex detection of DNA that originates from a specific cell-type |
EP3521454A1 (en) * | 2014-05-09 | 2019-08-07 | LifeCodexx AG | Detection of dna that originates from a specific cell-type and related methods |
US11062789B2 (en) | 2014-07-18 | 2021-07-13 | The Chinese University Of Hong Kong | Methylation pattern analysis of tissues in a DNA mixture |
US11984195B2 (en) | 2014-07-18 | 2024-05-14 | The Chinese University Of Hong Kong | Methylation pattern analysis of tissues in a DNA mixture |
US10364467B2 (en) | 2015-01-13 | 2019-07-30 | The Chinese University Of Hong Kong | Using size and number aberrations in plasma DNA for detecting cancer |
WO2017081047A1 (en) | 2015-11-10 | 2017-05-18 | Lifecodexx Ag | Detection of foetal chromosomal aneuploidies using dna regions that are differentially methylated between the foetus and the pregnant female |
US11753684B2 (en) | 2015-11-10 | 2023-09-12 | Eurofins Lifecodexx Gmbh | Detection of fetal chromosomal aneuploidies using DNA regions that are differentially methylated between the fetus and the pregnant female |
EP3168309A1 (en) | 2015-11-10 | 2017-05-17 | Lifecodexx AG | Detection of foetal chromosomal aneuploidies using dna regions that are differentially methylated between the foetus and the pregnant female |
US11435339B2 (en) | 2016-11-30 | 2022-09-06 | The Chinese University Of Hong Kong | Analysis of cell-free DNA in urine |
US11725251B2 (en) | 2018-09-27 | 2023-08-15 | Grail, Llc | Methylation markers and targeted methylation probe panel |
US11795513B2 (en) | 2018-09-27 | 2023-10-24 | Grail, Llc | Methylation markers and targeted methylation probe panel |
US11685958B2 (en) | 2018-09-27 | 2023-06-27 | Grail, Llc | Methylation markers and targeted methylation probe panel |
US11410750B2 (en) | 2018-09-27 | 2022-08-09 | Grail, Llc | Methylation markers and targeted methylation probe panel |
US12024750B2 (en) | 2020-10-01 | 2024-07-02 | Grail, Llc | Methylation markers and targeted methylation probe panel |
Also Published As
Publication number | Publication date |
---|---|
US20100323352A1 (en) | 2010-12-23 |
US7709194B2 (en) | 2010-05-04 |
US9862999B2 (en) | 2018-01-09 |
US20180155791A1 (en) | 2018-06-07 |
US8026067B2 (en) | 2011-09-27 |
AU2005250223B2 (en) | 2010-08-05 |
US10604808B2 (en) | 2020-03-31 |
US20200270694A1 (en) | 2020-08-27 |
WO2005118852A3 (en) | 2006-03-16 |
HK1102196A1 (en) | 2007-11-09 |
CA2568755C (en) | 2016-02-09 |
US20160258018A1 (en) | 2016-09-08 |
EP1751307A2 (en) | 2007-02-14 |
CA2568755A1 (en) | 2005-12-15 |
EP1751307B1 (en) | 2013-08-28 |
AU2005250223A1 (en) | 2005-12-15 |
US11597977B2 (en) | 2023-03-07 |
US20120003650A1 (en) | 2012-01-05 |
US20060019278A1 (en) | 2006-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11597977B2 (en) | Marker for prenatal diagnosis and monitoring | |
US7901884B2 (en) | Markers for prenatal diagnosis and monitoring | |
EP3875604B1 (en) | New fetal methylation marker |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005746652 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2568755 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005250223 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2005250223 Country of ref document: AU Date of ref document: 20050606 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005250223 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005746652 Country of ref document: EP |